Patient characteristics: complete cohort
| . | THRLBCL . | DLBCL . | P value . |
|---|---|---|---|
| n = 201 . | n = 5453 . | ||
| Age, y | |||
| Median (range) | 49.3 (19.4-73.7) | 58.5 (18.1-81.2) | <.0001 |
| Interval from diagnosis to HCT | |||
| >12 mo | 133 (66) | 3533 (65) | .7 |
| 0-12 mo | 68 (34) | 1913 (35) | |
| Missing | 0 | 7 | |
| Year of HCT | |||
| Median (range) | 2019 (2016-2021) | 2018 (2016-2021) | .34 |
| Sex | |||
| Female | 40 (20) | 2179 (40) | <.0001 |
| Male | 161 (80) | 3274 (60) | |
| Karnofsky index | |||
| <90 | 35 (19) | 1452 (29) | .004 |
| ≥90 | 149 (81) | 3619 (71) | |
| Missing | 17 | 382 | |
| HCT comorbidity index | |||
| 0 | 126 (71) | 3035 (64) | .12 |
| 1-2 | 29 (16) | 1008 (21) | |
| ≥3 | 22 (12) | 726 (15) | |
| Missing | 24 | 684 | |
| Transformed disease | |||
| No | 180 (92) | 4557 (87) | .03 |
| Yes | 15 (8) | 676 (12) | |
| Missing | 6 | 220 | |
| IPI | |||
| Low risk (0-1) | 20 (16) | 634 (19) | .3 |
| Low-intermediate risk (2) | 39 (31) | 878 (27) | |
| High-intermediate risk (3) | 44 (35) | 1004 (30) | |
| High risk (4 or 5) | 24 (19) | 796 (24) | |
| Missing | 74 | 2141 | |
| No. of lines of therapy | |||
| 2 | 157 (78) | 3977 (73) | .1 |
| ≥3 | 44 (22) | 1476 (27) | |
| Disease status at HCT | |||
| CR | 127 (63) | 3206 (59) | .21 |
| PR | 74 (37) | 2247 (41) | |
| Conditioning regimens | |||
| BEAM | 118 (59) | 2871 (53) | Not done |
| BEAM-like (TEAM, BeEAM, FEAM) | 36 (18) | 1010 (19) | |
| Other (BCNU-, CCNU-, TBI-based, other) | 47 (23) | 1572 (29) |
| . | THRLBCL . | DLBCL . | P value . |
|---|---|---|---|
| n = 201 . | n = 5453 . | ||
| Age, y | |||
| Median (range) | 49.3 (19.4-73.7) | 58.5 (18.1-81.2) | <.0001 |
| Interval from diagnosis to HCT | |||
| >12 mo | 133 (66) | 3533 (65) | .7 |
| 0-12 mo | 68 (34) | 1913 (35) | |
| Missing | 0 | 7 | |
| Year of HCT | |||
| Median (range) | 2019 (2016-2021) | 2018 (2016-2021) | .34 |
| Sex | |||
| Female | 40 (20) | 2179 (40) | <.0001 |
| Male | 161 (80) | 3274 (60) | |
| Karnofsky index | |||
| <90 | 35 (19) | 1452 (29) | .004 |
| ≥90 | 149 (81) | 3619 (71) | |
| Missing | 17 | 382 | |
| HCT comorbidity index | |||
| 0 | 126 (71) | 3035 (64) | .12 |
| 1-2 | 29 (16) | 1008 (21) | |
| ≥3 | 22 (12) | 726 (15) | |
| Missing | 24 | 684 | |
| Transformed disease | |||
| No | 180 (92) | 4557 (87) | .03 |
| Yes | 15 (8) | 676 (12) | |
| Missing | 6 | 220 | |
| IPI | |||
| Low risk (0-1) | 20 (16) | 634 (19) | .3 |
| Low-intermediate risk (2) | 39 (31) | 878 (27) | |
| High-intermediate risk (3) | 44 (35) | 1004 (30) | |
| High risk (4 or 5) | 24 (19) | 796 (24) | |
| Missing | 74 | 2141 | |
| No. of lines of therapy | |||
| 2 | 157 (78) | 3977 (73) | .1 |
| ≥3 | 44 (22) | 1476 (27) | |
| Disease status at HCT | |||
| CR | 127 (63) | 3206 (59) | .21 |
| PR | 74 (37) | 2247 (41) | |
| Conditioning regimens | |||
| BEAM | 118 (59) | 2871 (53) | Not done |
| BEAM-like (TEAM, BeEAM, FEAM) | 36 (18) | 1010 (19) | |
| Other (BCNU-, CCNU-, TBI-based, other) | 47 (23) | 1572 (29) |
B/CCNU, lomustin; BEAM, carmustin, etoposid, cytarabin, melphalan; BeEAM, bendamustin, etoposide, cytarabin, melphalan; FEAM, fotemustib, etoposide, cytarabin, melphalan; PR, partial remission; TBI, total body irradiation; TEAM, thiotepa, etoposide, cytarabin, melphalan.